Recombinant protein therapeutics, vaccines, and plasma products have a long record of
safety. However, the use of cell culture to produce recombinant proteins is still susceptible to …

The clinical development of cell therapies is revealing that extracellular vesicles (EVs) may
become very instrumental as subcellular therapeutic adjuncts in human medicine. EVs are …

This analysis examines the potential of “cultured meat” products made from edible animal
cell culture to measurably displace the global consumption of conventional meat …

The removal of xenotrpic murine leukemia virus (xMuLV) by size-exclusion filter paper
composed of 100% naturally derived cellulose was validated. The filter paper was produced …

As biopharmaceutical companies have optimized cell line and production culture process
development, titers of recombinant antibodies have risen steadily to 3–8 g/L for fed-batch …

Mille-feuille (“a thousand leaves”) paper is the first non-woven, wet-laid filter paper,
composed of 100% native cellulose, which is capable of removal of the “worst-case” model …

Although oral subunit vaccines are highly relevant in the fight against widespread diseases,
their high cost, safety and proper immunogenicity are attributes that have yet to be …

Virus filtration is a downstream unit operation in the manufacturing of biotherapeutics to
remove potential viral contaminations based on size exclusion. While even very small …

Over the last decade, multiple broadly neutralizing monoclonal antibodies (bN-mAbs) to the
HIV-1 envelope protein (Env) gp120 have been described. Many of these recognize …

Typical platform processes for biopharmaceutical products derived from animal cell lines
include a parvovirus filtration unit operation to provide viral safety assurance of the drug …